期刊文献+

HCV通过抑制T细胞IL-2分泌逃避人体免疫机制的实验研究 被引量:5

The Hepatitis C Virus Avoid Human Immune System by Inhibiting Interleukin-2 Secretion
暂未订购
导出
摘要 目的:探讨丙型肝炎病毒(hepatitisCvirus,HCV)抑制T细胞IL-2分泌的机制,为预防、诊断和治疗丙型肝炎提供新思路。方法:利用卟啉醇肉豆蔻酸乙酸酯(phorobol12-myristate13-acetate,PMA)、植物血凝素(phyto-haemagglutinin,PHA)、Ca2+以及抗CD3抗体(OrthoKungTcell3,OKT3)、抗CD81单克隆抗体以及HCV表面蛋白(envelopeproteinofHCV,EP)刺激jurkatT细胞,采用ELISA方法检测培养液中IL-2的产生量并讨论。结果:单独采用PMA和PHA,PHA和Ca2+,OKT3和抗CD81单克隆抗体刺激jurkatT细胞24h,会产生大量的IL-2。如果在采用上述刺激之前,分别使用抗CD81单克隆抗体或EP预处理jurkatT细胞1h,则在上述刺激之后IL-2的产量明显减少。结论:由于EP可与CD81分子特异结合,可以说明HCVEP通过T细胞表面的CD81分子抑制了IL-2的分泌,导致免疫功能受损。 Objective: To study the mechanism of hepatitis C viyus ( HCV) inhibit IL-2 secretion of human T cells, and try to find a new way to prevent, diagnose and treat the hepatitis caused by HCV. Methods: Phorobol 12-myris-tate 13-acetate (PMA) , phytohaemagglutinin (PHA) , Ca2+ (ionomycin) , anti-CD3 monoclonal antibody (Ortho Kung T cell 3, OKT3) , anti-CD81 monoclonal antibody and envelope protein (EP) of HCV were used to activate jurkat T cells. IL-2 was measured by ELISA. And the results were discussed. Results: Using PMA&PHA, PHA&ionomycin, OKT3&anti-CD81 antibody to activate jurkat T cells separately for 24h will produce a lot of IL-2. But if pretreat the cells by anti-CD81 antibody or EP for 1h, the production of IL-2 will be decreased observably. Conclusion: Because EP can bind with CD81 molecule specifically, it is well known that HCV can inhibit IL-2 production of T cell by the binding of EP and CD81, to induce the hurt of immune response.
作者 刁骋
出处 《沈阳医学院学报》 2005年第1期8-10,共3页 Journal of Shenyang Medical College
  • 相关文献

参考文献9

  • 1Lauer GM, Walker BD. Hepatitis C virus infections [J]. N Engl J Med, 2001, 345:41-52.
  • 2Pileri P, Uematsu Y, Campagnoli S. Banding of hepatitis C virus to CD81 [J]. Science, 1998, 282:938-941.
  • 3Petracca R, Falugi F, Galli G. Structure function analysis of hepatitis C virus envelope-CD81 binding [ J ]. Journal of Virology,2000, 74 :4824-4830.
  • 4Kitadokoro K. Structural biology of the human CD81, a receptor for hepatitis C virus [J]. Uirusu, 2004, 54(1): 39-47.
  • 5Wack A, Solidaini E, Tseng CT, et al. Binding of the hepatitis C virus envelope protein E2 to CD1 provides a co-stimulateory signal for human T cells [J]. Eur J lmmunol, 2001,31:166-175.
  • 6Malaguarnera M, Pistone G, Neri S, et al. Interleukin-2 plus ribavirin in versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment [J]. Bio Drugs, 2004, 18(6): 407-413.
  • 7Cecere A, Marotta F, Vangieri B, et al. Progressive liver injury in chronic hepatitis C infection is related to altered cellular immune response and to different cytokine profile [ J ]. Panminerva Med,2004, 46(3): 171-187.
  • 8Marinho RT, Pinto R,Santos ML, et al. Effects of interferon and ribavirin combination therapy on CD4 + proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C[J]. J Viral Hepat, 2004,11(3): 206-216.
  • 9Masciopinto F, Giovani C, Campagnoli S, et al. Association of hepatitis C virus envelope proteins with exosomes [ J ]. Eur J Immunol, 2004, 34(10): 2834.

同被引文献57

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部